Evidence map›Paper›PMID 33873265›Full record

ReviewEndocrinology and metabolism (Seoul, Korea)2021

Cardiorenal Protection in Diabetic Kidney Disease.

Jason F Lee, Ecaterina Berzan, Vikas S Sridhar, Ayodele Odutayo, David Z I Cherney

Registry-linked trialOpen access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Endocrinology and metabolism (Seoul, Korea), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07434791 (GOaL Directed-STrategic Approach With New Disease-modifying theraApies to Reduce Kidney and Cardiovascular Risk in Patients With Diabetic Kidney Disease), which is not on this map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07434791 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

GOaL Directed-STrategic Approach With New Disease-modifying theraApies to Reduce Kidney and Cardiovascular Risk in Patients With Diabetic Kidney Disease

TypeinterventionalSponsorSunnybrook Health Sciences CentreRan2026 to 2029Enrolled100ConditionsDiabetic Kidney Disease (DKD)ArmsEarly goal-directed Cardio-Kidney-Metabolic (CKM) care, Standard care (Comparison arm)
3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Personalizing Cardio-Kidney-Metabolic Therapy: Closer but Not There Yet.Journal of the American Society of Nephrology : JASN · 2026
    Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Jason F LeeToronto General Hospital Research Institute, University Health Network, ON, Canada.
Ecaterina BerzanToronto General Hospital Research Institute, University Health Network, ON, Canada.
Vikas S SridharToronto General Hospital Research Institute, University Health Network, ON, Canada.
Ayodele OdutayoDivision of Nephrology, Department of Medicine, University of Toronto, ON, Canada.
David Z I CherneyToronto General Hospital Research Institute, University Health Network, ON, Canada.
University Health Network · CASt. Michael's Hospital · CA

Funding

CIHR
6 · The paper itself

Abstract

Over the last 5 years there have been many new developments in the management of diabetic kidney disease. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter-2 (SGLT2) inhibitors were initially used for glycemic control, but more recent studies have now shown that their benefits extend to cardiovascular and kidney outcomes. The recent addition of data on the novel mineralocorticoid receptor antagonist (MRA) gives us another approach to further decrease the residual risk of diabetic kidney disease progression. In this review we describe the mechanism of action, key studies, and possible adverse effects related to these three classes of medications. The management of type 2 diabetes now includes an increasing number of medications for the management of comorbidities in a patient population at significant risk of cardiovascular disease and progression of chronic kidney disease. It is from this perspective that we seek to outline the rationale for the sequential and/or combined use of SGLT2 inhibitors, GLP-1 RA and MRAs in patients with type 2 diabetes for heart and kidney protection.

Indexed as

Cardiovascular DiseasesDiabetes Mellitus, Type 2Diabetic NephropathiesSodium-Glucose Transporter 2 InhibitorsHumansHypoglycemic AgentsHypoglycemic AgentsSodium-Glucose Transporter 2 InhibitorsCardiovascular diseasesDiabetes mellitus, type 2Diabetic nephropathiesGlucagon-like peptide-1 receptorHeart failureMineralocorticoid receptor antagonistsSodium-glucose transporter 2 inhibitors

Identifiers

PMID33873265
PMCPMC8090466
OpenAlexW3155932096

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.